Erika A Dobrota - JoVE Visualize

Showing results (1-10 of 4) with videos related to

Pageof 1

Sort By:

Molecular and Cellular Biology|February 28, 2007

CSK controls retinoic acid receptor (RAR) signaling: a RAR-c-SRC signaling axis is required for neuritogenic differentiationNandini Dey, Pradip K De, Mu Wang, et al.

Cancers|April 14, 2026

Reframing RB Tumor Suppressor Dysfunction as a Therapeutic Vulnerability in CancerRada Malko, Harlan E Shannon, Erika A Dobrota, et al.

Cancers|August 30, 2020

Systems Biology Approach Identifies Prognostic Signatures of Poor Overall Survival and Guides the Prioritization of Novel BET-CHK1 Combination Therapy for OsteosarcomaPankita H Pandya, Lijun Cheng, M Reza Saadatzadeh, et al.

Neoplasia (New York, N.Y.)|January 16, 2026

Dual CDK4/6-PI3K/mTOR inhibition reinforces cytostatic programs and tumor control in preclinical models of primary and metastatic osteosarcomaFarinaz Barghi, M Reza Saadatzadeh, Erika A Dobrota, et al.

Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:

Pageof 1

Molecular and Cellular Biology|February 28, 2007

CSK controls retinoic acid receptor (RAR) signaling: a RAR-c-SRC signaling axis is required for neuritogenic differentiationNandini Dey, Pradip K De, Mu Wang, et al.

Cancers|April 14, 2026

Reframing RB Tumor Suppressor Dysfunction as a Therapeutic Vulnerability in CancerRada Malko, Harlan E Shannon, Erika A Dobrota, et al.

Cancers|August 30, 2020

Systems Biology Approach Identifies Prognostic Signatures of Poor Overall Survival and Guides the Prioritization of Novel BET-CHK1 Combination Therapy for OsteosarcomaPankita H Pandya, Lijun Cheng, M Reza Saadatzadeh, et al.

Neoplasia (New York, N.Y.)|January 16, 2026

Dual CDK4/6-PI3K/mTOR inhibition reinforces cytostatic programs and tumor control in preclinical models of primary and metastatic osteosarcomaFarinaz Barghi, M Reza Saadatzadeh, Erika A Dobrota, et al.

Pageof 1